Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.

The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.

The trial will identify patients using NGS and an IHC assay, which Ideaya and Ventana codeveloped to confirm MTAP protein levels.

The French cancer center will use OncoDNA's blood-based next-generation sequencing test, OncoFollow, in its ongoing SCANDARE study.

At the annual meeting, researchers demonstrated how the growing real-world database can be useful in answering myriad research questions.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.